Company NovMetaPharma Co., Ltd.

Equities

A229500

KR7229500004

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-23 EDT			5-day change	1st Jan Change
7,250 ^KRW	-0.68%		-10.27%	-64.63%

05-27	NovMetaPharma Co., Ltd. cancelled the acquisition of SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction.	CI
2023	NovMetaPharma Co., Ltd. agreed to acquire SK Securities No.8 Special Purpose Acquisition Company in a reverse merger transaction	CI

NovMetaPharma Co., Ltd. is a Korea-based company mainly engaged in the development and sale of pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment is involved in the development and sale of diabetes treatment, obesity treatment, osteoporosis treatment, alzheimer's disease treatment, and autoimmune enhancers. The Health Functional Food segment is engaged in the manufacturing and sale of health functional food related to blood sugar, prostate health, comprehensive minerals, and cognitive improvement. It also produces and sells vinegar drinks. The Company distributes its products within the domestic market and to overseas markets, including America and China.

KRW in Million	2022	Weight	2023	Weight	Delta
Health Functional Food 100.0 %	31	100.0 %	14	100.0 %	-56.00%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	31	100.0 %	14	100.0 %	-56.00%

Managers	Title	Age	Since
Hoi-Yoon Jung CEO	Chief Executive Officer	45	-
Seon-Wook Hwang CEO	Chief Executive Officer	64	10-11-03
Heon-Jong Lee BRD	Director/Board Member	54	11-03-31
Johan Auwerx BRD	Director/Board Member	-	-
Chun-Su Lee AUD	Comptroller/Controller/Auditor	62	15-03-30

Members of the board	Title	Age	Since
Johan Auwerx BRD	Director/Board Member	-	-
Seon-Wook Hwang CEO	Chief Executive Officer	64	10-11-03
Heon-Jong Lee BRD	Director/Board Member	54	11-03-31
Mun-Jin Song BRD	Director/Board Member	54	13-12-31
Sang-Joon Kim BRD	Director/Board Member	63	18-06-14
In-Gyu Lee BRD	Director/Board Member	67	17-12-12
Jong-Man Seol BRD	Director/Board Member	65	19-03-26
Gyung-Tae Kim BRD	Director/Board Member	67	16-09-20
Hoi-Yoon Jung CEO	Chief Executive Officer	45	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,090,448	7,443,358 ( 67.12 %)	135 ( 0.001217 %)	67.12 %

Name	Equities	%	Valuation
Seon-Wook Hwang 9.360 %	1,038,030	9.360 %	5 M ₩
Mun-Jin Song 7.188 %	797,137	7.188 %	4 M ₩
Mi-jin Song 7.188 %	797,137	7.188 %	4 M ₩
Mun-Gi Song 3.594 %	398,568	3.594 %	2 M ₩
Jong-soon Song 3.594 %	398,568	3.594 %	2 M ₩
KX INNOVATION CO., LTD. 1.286 %	142,655	1.286 %	650 142 ₩
Heon-Jong Lee 0.7766 %	86,128	0.7766 %	392 523 ₩
Won-gyu Son 0.4833 %	53,596	0.4833 %	244 261 ₩
Chun-Su Lee 0.4406 %	48,860	0.4406 %	222 677 ₩
Jae-wook Kim 0.1711 %	18,978	0.1711 %	86 491 ₩

NovMetaPharma Co., Ltd.

13/F, Trees building 727 Eonju-ro

06050, Seoul

http://www.novmeta.com

address NovMetaPharma Co., Ltd.(A229500)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NOVMETAPHARMA CO., LTD.	-64.63%	45.42M
VERTEX PHARMACEUTICALS INCORPORATED	+16.45%	122B
REGENERON PHARMACEUTICALS, INC.	+21.96%	116B
ARGENX SE	+23.73%	27.03B
BIONTECH SE	-20.05%	20.36B
BEIGENE, LTD.	-16.28%	15.91B
GENMAB A/S	-16.52%	16.43B
WUXI APPTEC CO., LTD.	-44.35%	15.6B
SAREPTA THERAPEUTICS, INC.	+63.91%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+2.52%	13.59B

Bio Therapeutic Drugs